One-year outcome of the everolimus eluting, balloon expandable Promus Element and Promus Element Plus stent in the treatment of below-the-knee lesions in patients with critical limb ischemia.
To investigate the efficacy of the balloon expandable Promus Element and Promus Element Plus stent , coated with everolimus, in the treatment of short, focal infrapopliteal lesions. The PREVENT study was a prospective, multi-center, non-randomized, single arm study evaluating the safety and efficacy of the Promus Element and Promus Element Plus stent in the treatment of stenotic or occlusive lesions ≤40 mm long in the tibioperoneal arteries of patients with critical limb ischemia (CLI). A total of 70 study subjects were enrolled in a period of 26 months, between November 2012 and December 2014. The mean age was 77,84 (62-90; ± 6,62) years and 47 patients were men (67.1%). Mean lesion length was 22.83 (5-40; ± 8.78) mm. 44.3% of the lesions were occluded, whereas 55.7% were stenotic. Primary endpoint was primary patency at 12 months, defined as absence of restenosis (≥50% stenosis) or occlusion within the originally treated lesion based on angiography. Secondary outcomes included hemodynamic primary patency on duplex ultrasound (PSV ratio ≤2.4 ), limb salvage and freedom from target lesion revascularization (TLR). Technical and procedural success (<30% residual angiographic stenosis without major complications) was achieved in all 70 cases (100%). Primary patency was 93.8 % at 6 months and 86.2% at 1 year. Freedom from TLR was 93% at 1 year. Limb salvage rate at 12 month follow-up, defined as absence of major amputation, was 100%. This study shows the safety and efficacy of the everolimus eluting, balloon expandable Promus Element and Promus Element Plus stent in the treatment of below-the-knee lesions in patients with critical limb ischemia.